Akero Therapeutics (AKRO) said late Tuesday it priced an upsized public offering of about 5.3 million shares at $48 each and pre-funded warrants to purchase about 2 million shares at $47.9999 per warrant.
The company anticipates gross proceeds of $350 million.
Underwriters have a 30-day option to acquire up to about 1.1 million additional shares, the company said.
The offering is expected to close on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.